Please login to the form below

Not currently logged in
Email:
Password:

Nestlé acquires CM&D Pharma

Nestlé Health Science has acquired CM&D Pharma, a small UK company specialising in kidney disease, inflammatory bowel disease and colon cancer

Nestlé Health Science has acquired CM&D Pharma, a small UK company specialising in the research and development, marketing and sales of foods for specialist medical purposes. The company's portfolio comprises products tailored for patients with kidney disease, inflammatory bowel disease and colon cancer.

The financial details of the acquisition, which took place just one month after Nestle Health Science became operational, have not been disclosed. Nestlé Health Science is a fully-owned subsidiary of Nestlé SA and will develop science-based nutritional solutions to deliver personalised healthcare for medical conditions.

Commenting on the deal, Luis Cantarell, president and CEO of Nestlé Health Science said: "This acquisition is an excellent fit with Nestlé Health Sciences strategic goal of being a pioneer in the promising area of science-based nutrition. We share CM&D's commitment to use health science for improving the quality of people's lives, and this acquisition will help to reinforce our position in this opportunity. Additionally, CM&D will benefit from Nestlé Health Science's commitment to biomedical research, and the resources of the Nestlé Institute of Health Sciences." 

CM&D's leading product is Fostrap, a medical chewing gum for kidney patients with hyperphosphataemia (an elevated level of phosphate in the blood). Its other products include Reclonix for the treatment of abdominal pain often associated with Crohn's Disease; ulcerative colitis; or non-specific inflammatory bowel disease and Eviendep, a unique colon protector is intended to slow down the progression of polyps to colon cancer and to prevent their reoccurrence following removal.

CM&D founder, Danilo Casadei Massari, commented: "The Board of CM&D Pharma is confident that now, with a trade shareholder with unparallelled expertise and understanding of the science and the regulatory environment behind dietary management of health conditions, its product portfolio will be fully exploited.  We are also pleased to have maintained our promise to our original shareholders, and rewarded them for their faith in us."

Fasken Martineau LLP acted as legal adviser to CM&D on the transaction. 

3rd February 2011

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Wilmington Healthcare

A heritage to envy Wilmington Healthcare brings together the data intelligence specialisms of Binley’s, NHiS, Wellards and HSJ to create...

Latest intelligence

segmentation_pie_thumb.jpg
If you’re not thinking segmentation, you’re not thinking
Having a background in market research I’ve been lucky to work on a number of customer segmentations in my time but working in creative communications it is still too rare...
Improving Outcomes in the Treatment of Opioid Dependence Highlights Report
The 16th annual ‘Improving Outcomes in the Treatment of Opioid Dependence’ (IOTOD)conference took place at the Hilton Madrid Airport hotel on 15–16 May 2018....
Londonvelophobia (fear of cycling in London) – debunked
...

Infographics